Inhibikase Therapeutics, Inc.
IKT
$2.41
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -60.64M | -50.96M | -48.26M | -47.66M | -41.50M |
| Total Depreciation and Amortization | 23.70K | 47.90K | 60.60K | 67.20K | 50.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.83M | 16.49M | 20.36M | 23.46M | 20.14M |
| Change in Net Operating Assets | 1.17M | -1.32M | 55.90K | -1.48M | 1.41M |
| Cash from Operations | -42.61M | -35.74M | -27.79M | -25.62M | -19.90M |
| Capital Expenditure | 0.00 | 0.00 | -13.40K | -13.40K | -13.40K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -115.24M | -99.49M | 2.07M | -36.60M | -5.32M |
| Cash from Investing | -115.24M | -99.49M | 2.05M | -36.61M | -5.34M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 111.33M | 111.36M | 108.46M | 99.97M | 99.90M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -14.50K | 0.00 | 0.00 | -385.10K | -- |
| Cash from Financing | 111.31M | 111.36M | 108.46M | 99.58M | 99.90M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -46.54M | -23.87M | 82.73M | 37.36M | 74.66M |